KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Accumulated Expenses: 2023-2024

Historic Accumulated Expenses for Aurinia Pharmaceuticals (AUPH) over the last 2 years, with Dec 2024 value amounting to $65.0 million.

  • Aurinia Pharmaceuticals' Accumulated Expenses was N/A to $49.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.5 million, marking a year-over-year change of. This contributed to the annual value of $65.0 million for FY2024, which is 29.78% up from last year.
  • Aurinia Pharmaceuticals' Accumulated Expenses amounted to $65.0 million in FY2024, which was up 29.78% from $50.1 million recorded in FY2023.
  • Over the past 5 years, Aurinia Pharmaceuticals' Accumulated Expenses peaked at $65.0 million during FY2024, and registered a low of $50.1 million during FY2023.
  • Its 2-year average for Accumulated Expenses is $57.5 million, with a median of $57.5 million in 2023.
  • Data for Aurinia Pharmaceuticals' Accumulated Expenses shows a peak YoY increased of 29.78% (in 2024) over the last 5 years.
  • Over the past 2 years, Aurinia Pharmaceuticals' Accumulated Expenses (Yearly) stood at $50.1 million in 2023, then climbed by 29.78% to $65.0 million in 2024.